AgingResearch.NewsJoin free

Esteve Healthcare

Company

Esteve Healthcare develops one asset, in phase 3 (Co-crystal E-58425 in acute post surgical pain). Mostly small molecule acting on inflammation, PTGS2 and SLC6A2.

1
Asset
Furthest stage
Phase 3
1
Trial
0
Signals

Pipeline

1

  • Co-crystal E-58425

    Co-crystal of tramadol and celecoxib providing dual opioid and anti-inflammatory analgesia via COX-2 and mu-opioid receptor modulation

    Phase 3, Small molecule, Inflammation, PTGS2, acute post surgical pain

Full company profiles: pipeline, trials, funding and people.

See Pro

Subsidiaries

1

In the full profile

  • Evidence behind the mechanisms6
  • Trials2
  • Similar companies6

Intelligence